Patient Clinical Profile

  • Patient Age: 63
  • Gender: Female
  • Visit Type: Cancer Patient – Stage III Ovarian Cancer
  • Visit notes: Patient has no family history

    NCCN Guidelines state that all patients diagnosed with ovarian cancer, including fallopian tube and primary peritoneal cancers, should receive genetic testing.1

    This patient’s Gynecologic Oncologist did the right thing by identifying her ovarian cancer as an indication that meets criteria for hereditary cancer testing. Her doctor ordered a myRisk gene panel to determine if her BRCA status would make her eligible for treatment with LynparzaTM, an FDA approved PARP inhibitor. Additionally, the myRisk panel would identify any mutations in genes outside of BRCA1 and BRCA2. In a study of 3,088 patients with ovarian cancer, 35% of the pathogenic cancer-associated mutations were identified in genes other than BRCA1 and BRCA2.2

    Ordering a comprehensive panel for treatment information as well as hereditary cancer risk is critical.


RESULT: Positive

Patient may benefit from treatment with LynparzaTM: Lynparza is the first oral prescription medicine for women with BRCA-mutated advanced ovarian cancer who have received 3 or more prior chemotherapy regimens.

RESULT: Positive
MSH2 (Lynch syndrome)

MSH2 Cancer Risk Management Table

*These risks do not represent a comprehensive list of the cancer risks associated with an MSH2 mutation


  • Up to 82% future cancer risk
  • Colonoscopy every 1 to 2 years


  • Up to 13% future cancer risk
  • Upper endoscopy every 3 to 5 years

Small Bowel

  • Up to 6% future cancer risk
  • Upper endoscopy every 3 to 5 years


  • Up to 6% future cancer risk

In this particular case…

Not only did this patient learn that she is BRCA1 positive and may benefit from treatment with LynparzaTM, an FDA approved PARP inhibitor, but she also learned of her MSH2 mutation (Lynch syndrome). Her Gynecologic Oncologist now has more insight into this patient’s future cancer risks and medical management considerations.

Myriad myRisk Hereditary Cancer test increases mutation detection by 40-50% in patients appropriate for HBOC or Lynch testing.3-5

Hereditary Cancer Panels:

✔ Save money and time

✔ Allow for earlier intervention

✔ Reduce false negative results

Since 2016, NCCN guidelines have recognized the impact that multi-gene panel testing has in changing the clinical approach to testing at-risk individuals.6

Order a Test Kit


  1. National Comprehensive Cancer Network Guidelines Version 2 2016.3.15.16
  2. Langer LR, Evans B, Saam J, Wenstrup RJ. The Genetic Basis of Ovarian Cancer: Identifying Hereditary Ovarian Cancer Using a 25-gene Panel. Presented at SGO Annual Meeting on Women’s Cancer. March 2015; Chicago, IL
  3. Sharma, L., et al. (2014, December) Spectrum of Mutations Identified in a 25-gene Hereditary Cancer Panel for Patients with Breast Cancer. Presented at SABCS, San Antonio, TX.
  4. Yurgelun, MB., et al., Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients with Suspected Lynch Syndrome, Gastroenterology, (2015, May).
  5. Tung N, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015 Jan 1;121(1):25-33.
  6. National Comprehensive Cancer Network. “NCCN Clinical Practice Guidelines in Oncology®Genetic/Familial High-Risk Assessment: Breast and Ovarian” Version 1.2017. Available at:

Leave a Reply

Your email address will not be published. Required fields are marked *